Research Horizons


Can a “Prodrug” Defeat Treatment-Resistant SHH-Medulloblastoma?

MRI image of a brain tumor

A study published Aug. 29, 2019, in Cancer Cell used new forms of technology to find potential new ways to treat a deadly form of brain cancer.

Existing small-molecule inhibitors can target the oncogenic cascade pathways that cause SHH-medullablastoma tumor initiation and recurrence, says Q. Richard Lu, PhD, senior author and scientific director of the Brain Tumor Center at Cincinnati Children’s.

Read more about how immature oligodendrocyte progenitor cells in the brain—which can assume stem-cell-like qualities—grow out of control to form medulloblastoma tumors and about a “prodrug” concept that might stop the cascade.

Publication Information
Original title: Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse
Published in: Cancer Cell
Publish date: Aug. 29, 2019
Read the study

Research By

Q. Richard Lu, PhD
Scientific Director, Brain Tumor Center
A major focus of our lab research is to elucidate the transcriptional, posttranscriptional, epigenetic and signaling regulatory networks that govern glial progenitor fate specification, myelination and glioma formation.